Counselors in Concord Township, OH Accepting Medicare
4 Counselors found. Showing 1 - 4
 Lori Jean Radwancky, PRS Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 7301 Ravenna Rd, Concord Township, OH 44077 Phone: 440-205-2684 |
Samantha Emch, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 7725 Skylineview Dr, Concord Township, OH 44060 Phone: 602-904-1988 |
Teresa I Hobbs, CDCA Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 7301 Painesville Ravenna Rd, Concord Township, OH 44077 Phone: 440-354-3726 Fax: 440-754-8029 |
Aishah C Braxton Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 7185 Summerhill Dr, Concord Township, OH 44077 Phone: 440-589-0031 |
News Archive
Age of gluten introduction does not reduce risk of celiac disease in at-risk infants
Based on new evidence, the age of introduction of gluten into the infant diet - or the practice of introducing gluten during breast-feeding - does not reduce the risk of celiac disease in infants at risk, according to a Position Paper of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.
Diagnosis and referrals for kidney disease fall well short of need
Results of a national study of 304 U.S. physicians, in which "mock" patients' symptoms were presented for diagnosis, suggest that a sizeable percentage of primary care doctors probably fail to properly diagnose and refer patients with chronic kidney disease (CKD).
Supreme Court gives nuns temporary reprieve on health law's contraceptive mandate
The Supreme Court on Friday afternoon gave an order of Roman Catholic nuns some added protection against the enforcement of a part of the Affordable Care Act, and spared them -; for now -; from having to file a government form in order to be exempt.
Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.
› Verified 2 days ago